HK Stock Market Move | Dajin Heavy Industry (01081) falls over 6%; shipment pace and foreign exchange drag down Q3 report; Citi cuts company's net profit forecast.
Dajin Heavy Industry (01081) share price moved lower, falling 5.81% as of press time to HK$21.74, with turnover of HK$47.4164 million.
Dajin Heavy Industry (01081) shares moved lower, down 5.81% as of press time at HK$21.74, with turnover of HK$47.4164 million.
On the news front, Dajin Heavy Industry's recently released 2026 third-quarter report showed revenue of RMB4.36 billion for the first three quarters, down 5.05% year-on-year, and net profit attributable to shareholders of RMB710 million, down 19.97% year-on-year. Third-quarter revenue was RMB1.111 billion, down 36.68% year-on-year; net profit attributable to shareholders was RMB110 million, down 67.85% year-on-year.
The company's third-quarter results were mainly affected by shipment pace and foreign exchange. According to the announcement, excluding the impact of exchange rates, the company achieved net profit of approximately RMB860 million in the first three quarters, up approximately 6% year-on-year. Citi cut the company's net profit forecasts for 2026 to 2028 by 23% to 29%, mainly due to slower-than-expected monopile deliveries, reflecting uncertain subsidy prospects and rising interest rates that reduce returns.
Related Articles

Citi: CITIC BANK (00998) Delivers Solid Q3 Results Benefiting from Improved Cost Efficiency; Profit Growth Trend Outperforms Management Guidance

HK Stock Market Move | PATEO (02889) rose over 10% in late trading; directors and senior management voluntarily committed to a lock-up; the company reached a global supply partnership with Jeep.

Astrazeneca PLC Sponsored ADR (AZN.US) Q3 profit growth exceeds expectations, with oncology drugs as the main growth driver.
Citi: CITIC BANK (00998) Delivers Solid Q3 Results Benefiting from Improved Cost Efficiency; Profit Growth Trend Outperforms Management Guidance

HK Stock Market Move | PATEO (02889) rose over 10% in late trading; directors and senior management voluntarily committed to a lock-up; the company reached a global supply partnership with Jeep.

Astrazeneca PLC Sponsored ADR (AZN.US) Q3 profit growth exceeds expectations, with oncology drugs as the main growth driver.






